Takeda and Lundbeck announce Brintellix for treatment of MDD

DEERFIELD, Ill. — Takeda Pharmaceuticals U.S.A. and Lundbeck on Tuesday announced the availability of Brintellix (vortioxetine) — a once-daily oral antidepressant for treatment of major depressive disorder in adults — in pharmacies across the United States.



“MDD continues to be a challenging condition to manage, and we are proud to make Brintellix available as a new treatment option for people struggling with major depression,” said Douglas Cole, president of Takeda Pharmaceuticals U.S.A.



The clinical trial evaluating the safety and efficacy of the drug was comprised of seven studies, including six- to eight-week short-term studies and one 24- to 64-week long-term maintenance study that demonstrated significant improvements in overall symptoms of depression in adults with MDD, according to the companies.



“Our passion for helping people living with MDD has been the inspiration for advancing Brintellix from the laboratory through clinical studies, and now into the hands of those who need it,” said Staffan Schüberg, president of Lundbeck U.S. “This same passion fuels our ongoing commitment to supporting people with this often chronic and complex disease.”